How Chemotherapy Affects Your Feet

Cancer chemotherapy treats disease by targeting rapidly dividing cells — unfortunately, this mechanism affects not only cancer cells but also the rapidly dividing cells of peripheral nerves, skin, and nails, creating a range of foot side effects that can significantly impact quality of life during and after treatment. Understanding these effects allows patients and oncology teams to take proactive measures that prevent complications and maintain foot function and comfort through the treatment process.

The specific foot problems that develop depend on which chemotherapy agents are used, the cumulative dose, treatment duration, and individual patient susceptibility. Some agents (platinum compounds, taxanes, vinca alkaloids) predominantly cause neuropathy. Others cause skin and nail changes. Some cause multiple effects simultaneously. Patients undergoing treatment should be informed about the foot side effects of their specific regimen so they can monitor their feet and report problems early when they are most treatable.

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Chemotherapy-induced peripheral neuropathy is the most common and potentially most serious foot complication of cancer treatment. It affects approximately 30-40% of chemotherapy patients and can persist for months to years after treatment completion — sometimes permanently. CIPN occurs because certain chemotherapy drugs damage the peripheral nerves by disrupting microtubules, causing oxidative stress, impairing mitochondrial function, or altering ion channel activity.

The drugs most commonly causing CIPN include platinum compounds (cisplatin, carboplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), vinca alkaloids (vincristine, vinblastine), and bortezomib. CIPN typically begins in a “stocking-glove” distribution — affecting the most distal extremities first, then progressing proximally as treatment continues or cumulative dose increases.

Symptoms of CIPN affecting the feet include numbness, tingling, burning, and shooting or electric pain. Some patients describe feelings of walking on glass, wearing thick socks constantly, or having their feet feel like they belong to someone else. The sensory symptoms are often accompanied by balance disturbance from impaired proprioception, creating fall risk. Motor weakness affecting the feet and ankles can develop in severe cases.

Monitoring for CIPN is essential during chemotherapy. Report any new foot numbness, tingling, or burning to your oncologist promptly — dose reduction or changing agents is sometimes warranted when CIPN becomes significant, as preventing permanent nerve damage is more important than maintaining a specific dose level in many cases. The severity of CIPN often dictates treatment modifications that balance cancer control against quality of life.

Palmar-Plantar Erythrodysesthesia: Hand-Foot Syndrome

Palmar-plantar erythrodysesthesia (PPE), also known as hand-foot syndrome or hand-foot skin reaction, is a specific side effect of certain chemotherapy agents — particularly capecitabine (Xeloda), fluorouracil (5-FU) continuous infusion, and targeted therapies including sorafenib, sunitinib, and other multi-kinase inhibitors. PPE causes redness, swelling, pain, blistering, and peeling of the palms and soles.

The mechanism involves drug accumulation in eccrine sweat gland ducts, particularly in the palms and soles which have the highest sweat gland density. Friction and pressure on these areas worsens the condition — activities that would normally be innocuous (walking, wearing shoes, gripping objects) become painful.

Preventive measures are critical and should begin before symptoms develop. These include wearing padded, well-fitting footwear to reduce friction; avoiding barefoot walking; applying thick emollient creams or petroleum jelly to the soles before activities; soaking feet in cool water; and avoiding excessive heat. Dose modification by the oncologist is the most powerful intervention when symptoms are severe. Topical corticosteroids reduce inflammation and may accelerate symptom resolution.

Nail Changes From Chemotherapy

Chemotherapy-related nail changes affect up to 50% of patients on certain regimens. These include onycholysis (separation of the nail from the nail bed), nail discoloration, Beau’s lines (transverse grooves marking periods of nail plate growth arrest), brittle or fragile nails, and subungual hematomas. Taxane-based regimens (particularly docetaxel) are particularly associated with nail toxicity.

Nail changes are not merely cosmetic — onycholysis creates space under the nail where bacteria and fungi can establish infections, and separated, loose nails are vulnerable to traumatic avulsion. Keeping affected nails clean and dry, using topical antifungals prophylactically, and cutting nails short to reduce leverage reduces these risks. Dark-colored nail polish during treatment has been studied as a means of reducing nail toxicity, with some positive results from the photoprotective properties of dark pigments.

If nails become significantly separated, infected, or painful, podiatric evaluation can provide appropriate management — including careful removal of loose or infected nail portions and appropriate wound care — without disrupting chemotherapy treatment.

Protecting Your Feet During Cancer Treatment

Several protective foot care strategies apply across multiple chemotherapy regimens. Inspect feet daily for redness, blistering, breaks in skin, nail changes, or any signs of infection. Chemotherapy-related immunosuppression makes infections potentially more serious than in healthy individuals — any wound or infection requires prompt reporting to your oncology team and potentially to a podiatrist.

Wear well-fitting shoes with ample cushioning and soft materials that don’t create friction pressure over vulnerable skin. Avoid barefoot walking even at home. Keep feet clean and moisturized but avoid products with fragrance or potential irritants. Wear moisture-wicking socks and change them if wet. Avoid very hot baths or showers — thermal sensitivity from CIPN makes temperature perception unreliable, increasing burn risk.

At Balance Foot & Ankle, we work with oncology teams to provide specialized foot care for cancer patients undergoing chemotherapy. We understand the unique challenges of foot care in immunocompromised patients, the importance of not disrupting oncology treatment schedules, and the specific management approaches that minimize foot complications during this difficult time. If you or a family member undergoing chemotherapy has foot concerns, please reach out.

Foot or Ankle Pain? We Can Help.

Balance Foot & Ankle — Howell & Bloomfield Township, MI

📅 Book Online
📞 (810) 206-1402

Dr. Tom Biernacki, DPM

Affiliate Disclosure: This page contains affiliate links to products we recommend. If you purchase through these links, Balance Foot & Ankle may earn a small commission at no additional cost to you. We only recommend products we use with our patients.

Dr. Tom Biernacki, DPM is a double board-certified podiatrist and foot & ankle surgeon at Balance Foot & Ankle Specialists in Southeast Michigan. With over a decade of clinical experience, he specializes in heel pain, bunions, diabetic foot care, sports injuries, and minimally invasive surgery. Dr. Biernacki is a member of the APMA and ACFAS, and his patient education content on MichiganFootDoctors.com and YouTube has reached over one million views.